In the five patients with metastatic RCC treated with a combination of anti-CTLA4 and anti–PD-1 antibodies, we found no relationship between CD8-positive T cells in the tumor microenvironment in core-needle biopsy for primary renal tumors and treatment response. Here, CTLA4 is linked to renal cell carcinoma.